

## FITC-labeled Tominersen sodium

<b>Cat. No.:</b>	HY-150236
<b>Molecular Weight:</b>	7654
<b>Target:</b>	Huntingtin
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### FITC-labeled Tominersen

#### SOLVENT & SOLUBILITY

##### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (13.07 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		Concentration	1 mg	5 mg	10 mg
	1 mM		0.1307 mL	0.6533 mL	1.3065 mL
	5 mM		0.0261 mL	0.1307 mL	0.2613 mL
	10 mM		0.0131 mL	0.0653 mL	0.1307 mL

Please refer to the solubility information to select the appropriate solvent.

#### BIOLOGICAL ACTIVITY

##### Description

FITC-labeled Tominersen (sodium) is the Tominersen labeled with FITC. Tominersen (RG6042) is a second-generation 2'-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington's disease (HD).

#### REFERENCES

- [1]. Tabrizi SJ, et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med. 2019 Jun 13;380(24):2307-2316.
- [2]. Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012 Jun 21;74(6):1031-44.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA